Heat shock protein derived from a non-autologous tumour can be used as an anti-tumour vaccine

David G. Casey; Stephen Todryk; Tharappel James; Joanne Lysaght; Andrew Bateman; Alan A. Melcher

doi:10.1046/j.1365-2567.2003.01726.x

Heat shock protein derived from a non-autologous tumour can be used as an anti-tumour vaccine

David G. Casey, Stephen Todryk, Tharappel James, Joanne Lysaght, Andrew Bateman, Alan A. Melcher

Applied Sciences

Research output: Contribution to journal › Article › peer-review

23 Citations (Scopus)

Abstract

Antigenic cross-reactivity between certain tumours has allowed the development of more widely applicable, major histocompatibility complex-disparate (allogeneic) whole-cell vaccines. This principle should also allow heat shock proteins (hsp) derived from certain tumours (and carrying cross-reactive antigens) to be used as vaccines to generate anti-tumour immunity in a range of cancer patients. Here, hsp70 derived from gp70-antigen+ B16 melanoma generated cytotoxic-T-lymphocyte-mediated immune protection in BALB/c mice against challenge with gp70-antigen+ CT26 colorectal tumour cells. Using ovalbumin as a model tumour antigen, it is shown that hsp70 enhances peptide re-presentation by dendritic cells via class I over equimolar whole ovalbumin antigen. However, while transfection of tumour cells with inducible hsp70 increases hsp yield from tumours, it does not enhance antigen recognition via purified hsp70 nor via whole cells or their lysate.

Original language	English
Pages (from-to)	105-111
Journal	Immunology
Volume	110
Issue number	1
DOIs	https://doi.org/10.1046/j.1365-2567.2003.01726.x
Publication status	Published - Aug 2003

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1046/j.1365-2567.2003.01726.x

Cite this

@article{70dbacf92c344fa8aa659b92d392e570,

title = "Heat shock protein derived from a non-autologous tumour can be used as an anti-tumour vaccine",

abstract = "Antigenic cross-reactivity between certain tumours has allowed the development of more widely applicable, major histocompatibility complex-disparate (allogeneic) whole-cell vaccines. This principle should also allow heat shock proteins (hsp) derived from certain tumours (and carrying cross-reactive antigens) to be used as vaccines to generate anti-tumour immunity in a range of cancer patients. Here, hsp70 derived from gp70-antigen+ B16 melanoma generated cytotoxic-T-lymphocyte-mediated immune protection in BALB/c mice against challenge with gp70-antigen+ CT26 colorectal tumour cells. Using ovalbumin as a model tumour antigen, it is shown that hsp70 enhances peptide re-presentation by dendritic cells via class I over equimolar whole ovalbumin antigen. However, while transfection of tumour cells with inducible hsp70 increases hsp yield from tumours, it does not enhance antigen recognition via purified hsp70 nor via whole cells or their lysate.",

author = "Casey, {David G.} and Stephen Todryk and Tharappel James and Joanne Lysaght and Andrew Bateman and Melcher, {Alan A.}",

year = "2003",

month = aug,

doi = "10.1046/j.1365-2567.2003.01726.x",

language = "English",

volume = "110",

pages = "105--111",

journal = "Immunology",

issn = "0019-2805",

publisher = "Wiley",

number = "1",

}

TY - JOUR

T1 - Heat shock protein derived from a non-autologous tumour can be used as an anti-tumour vaccine

AU - Casey, David G.

AU - Todryk, Stephen

AU - James, Tharappel

AU - Lysaght, Joanne

AU - Bateman, Andrew

AU - Melcher, Alan A.

PY - 2003/8

Y1 - 2003/8

N2 - Antigenic cross-reactivity between certain tumours has allowed the development of more widely applicable, major histocompatibility complex-disparate (allogeneic) whole-cell vaccines. This principle should also allow heat shock proteins (hsp) derived from certain tumours (and carrying cross-reactive antigens) to be used as vaccines to generate anti-tumour immunity in a range of cancer patients. Here, hsp70 derived from gp70-antigen+ B16 melanoma generated cytotoxic-T-lymphocyte-mediated immune protection in BALB/c mice against challenge with gp70-antigen+ CT26 colorectal tumour cells. Using ovalbumin as a model tumour antigen, it is shown that hsp70 enhances peptide re-presentation by dendritic cells via class I over equimolar whole ovalbumin antigen. However, while transfection of tumour cells with inducible hsp70 increases hsp yield from tumours, it does not enhance antigen recognition via purified hsp70 nor via whole cells or their lysate.

AB - Antigenic cross-reactivity between certain tumours has allowed the development of more widely applicable, major histocompatibility complex-disparate (allogeneic) whole-cell vaccines. This principle should also allow heat shock proteins (hsp) derived from certain tumours (and carrying cross-reactive antigens) to be used as vaccines to generate anti-tumour immunity in a range of cancer patients. Here, hsp70 derived from gp70-antigen+ B16 melanoma generated cytotoxic-T-lymphocyte-mediated immune protection in BALB/c mice against challenge with gp70-antigen+ CT26 colorectal tumour cells. Using ovalbumin as a model tumour antigen, it is shown that hsp70 enhances peptide re-presentation by dendritic cells via class I over equimolar whole ovalbumin antigen. However, while transfection of tumour cells with inducible hsp70 increases hsp yield from tumours, it does not enhance antigen recognition via purified hsp70 nor via whole cells or their lysate.

U2 - 10.1046/j.1365-2567.2003.01726.x

DO - 10.1046/j.1365-2567.2003.01726.x

M3 - Article

VL - 110

SP - 105

EP - 111

JO - Immunology

JF - Immunology

SN - 0019-2805

IS - 1

ER -

Heat shock protein derived from a non-autologous tumour can be used as an anti-tumour vaccine

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this